Person:
AYDINLAR, ALİ

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

AYDINLAR

First Name

ALİ

Name

Filters

2013 - 2019102020 - 20231
Reset filters

Settings

Search Results

Now showing 1 - 10 of 11
  • Thumbnail Image
    Publication
    Association of aortic diameters with coronary artery disease severity and albumin excretion
    (Hindawi, 2015-04-08) Özdemir, Bülent; Emul, Ali; Özdemir, Levent; Sağ, Saim; Biçer, Murat; Aydınlar, Ali; ÖZDEMİR, BÜLENT; Sağ, Saim; BİÇER, MURAT; AYDINLAR, ALİ; Tıp Fakültesi; Kardiyoloji Ana Bilim Dalı; 0000-0002-8974-8837; 0000-0001-8404-8252; AAW-9185-2020; ABC-2231-2020; AAI-6632-2021; JHE-3353-2023
    Introduction. Aortic diameters, aortic distensibility, microalbuminuria, coronary artery disease which are all together related to vascular aging are investigated in this paper. Methods. Eighty consecutive nondiabetic patients undergoing elective coronary angiography were enrolled into the study. Systolic and diastolic aortic diameters, aortic distensibility, CAD severity by angiogram with the use of Gensini scoring, and albumin excretion rates were determined. Results. Cases with CAD had significantly larger systolic (30,72 +/- 3,21mm versus 34,19 +/- 4,03 mm for cases without and with CAD, resp.) and diastolic aortic diameters measured 3 cm above aortic valve compared to patients without CAD (33,56 +/- 4,07 mm versus 29,75 +/- 3,12 mm). The systolic and diastolic diameters were significantly higher in albuminuria positive patients compared to albuminuria negative patients (p = 0.017 and 0.008, resp., for systolic and diastolic diameters). Conclusion. In conclusion aortic diameters are increased in patients with coronary artery disease and in patients with microalbuminuria. In CAD patients, systolic blood pressure, pulse pressure, aortic systolic and diastolic pressure, and albumin excretion rate were higher and aortic distensibility was lower.
  • Thumbnail Image
    Publication
    Coronary risk factors and coronary angiography results of 12.257 patients
    (Elsevier, 2013-10-29) Günay, Şeyda; Serdar, Osman Akın; Özyılmaz, Sinem Özbay; Dereli, Seçkin; Aydınlar, Ali; Baran, İbrahim; Özdemir, Bülent; Yeşilbursa, Dilek; Güllülü, Sümeyye; GÜNAY POLATKAN, ŞEYDA; SERDAR, OSMAN AKIN; Özyılmaz, Sinem Özbay; Dereli, Seçkin; AYDINLAR, ALİ; Baran, İbrahim; ÖZDEMİR, BÜLENT; YEŞİLBURSA, DİLEK; GÜLLÜLÜ, NAZMİYE SÜMEYYE; Tıp Fakültesi; Kardiyoloji Ana Bilim Dalı; 0000-0003-1744-8883; 0000-0002-7788-9739; 0000-0003-0090-3835; AAF-5116-2019; AAG-8709-2020; AAI-5350-2021; AAI-6632-2021; AAJ-3962-2020; AAB-5861-2021; CDA-1396-2022; JHE-3353-2023; EHA-0046-2022; JGR-6552-2023
  • Thumbnail Image
    Publication
    Myocardial performance is impaired in patients with branch retinal vein occlusion
    (Sage Publications, 2015-02-01) Kaderli, Berkant; Kaderli, Aysel Aydın; Güllülü, Sümeyye; İnan, Ümit Ubeyt; Şentürk, Tunay; Aydınlar, Ali; Yücel, Ahmet Ali; Avcı, Remzi; Kaderli, Berkant; GÜLLÜLÜ, NAZMİYE SÜMEYYE; ŞENTÜRK, TUNAY; AYDINLAR, ALİ; YÜCEL, AHMET ALİ; Kaderli, Aysel Aydın; Tıp Fakültesi; Göz Hastalıkları Ana Bilim Dalı; AAI-6632-2021; C-1517-2017; FDM-9757-2022; CXL-7581-2022; EXG-3181-2022; JYV-1141-2024
    Objective To investigate whether the Tei index, which is an indicator of global myocardial function and an independent predictor of cardiac death, is increased in patients with branch retinal vein occlusion (BRVO).Methods The Tei index was used to evaluate myocardial performance, in addition to conventional echocardiographic evaluation of myocardial structural and functional changes, in patients with BRVO, patients with hypertension and healthy controls.Results Out of 36 patients with BRVO (18 female, 18 male; 17 hypertensive, 19 normotensive), 29 patients with hypertension (15 female, 14 male) and 28 healthy controls (15 female, 13 male), there were no significant between-group differences in age and sex. The mitral A wave was higher and mitral E/A ratio, mitral E wave and ejection time were lower, in patients with BRVO than in healthy controls. Mean Tei index was significantly higher in the BRVO group than in patients with hypertension or healthy controls. Compared with healthy controls, the Tei index was significantly higher in hypertensive and normotensive patients with BRVO.Conclusion Myocardial performance is decreased in patients with BRVO, independent of whether or not they have hypertension.
  • No Thumbnail Available
    Publication
    The effects of fetuin-a levels on aortic stenosis
    (Derman Medical Publ, 2016-07-01) Tütüncü, Ahmet; Kustarcı, Taner; Özbek, Can; Aydınlar, Ali; AYDINLAR, ALİ; Yeşilbursa, Dilek; YEŞİLBURSA, DİLEK; Tıp Fakültesi; Kardiyoloji Ana Bilim Dalı; AAI-6632-2021; EHA-0046-2022
    Aim: We aimed to investigate the relation between fetuin-A and calcific aortic stenosis in non diabetic patients whose renal function were normal. Material and Method: 26 patients followed for aortic stenosis by our cardiology clinic for outpatients and 25 voluntary healthy subjects were included in the study. The fetuin-A levels were measured from the venous blood samples of the study population. All patients underwent transthorasic echocardiography, the aortic valvular area and left ventricular parameters of the patients were measured. Results: The average age of the patients in degenerative aortic stenosis group was significantly higher than the control group. The parameters related to aortic valve were naturally higher in patients with dejenerative aortic valve. There was no significant difference between two groups about fetuin-A levels. Further more there was no significant relation between fetuin-a levels and aortic stenosis severity. Discussion: In conclusion fetuin-A is a multifunctional glycoprotein that plays important role in systemic calcification inhibition and valvular calcification. Finally aortic stenosis is an active process and larger studies that investigate the relation between fetuin-a and the progression and prognosis of aortic stenosis are needed.
  • Thumbnail Image
    Publication
    Serum fetuin-a levels for the detection and evaluation of the left ventricular systolic heart failure
    (Elsevier, 2013-10-29) Keçebaş, Mesut; Güllülü, Sümeyye; Sağ, Saim; Açıkgöz, Ebru; Besli, Feyzullah; Şentürk, Tunay; Kaderli, Aysel Aydın; Özdemir, Bülent; Baran, İbrahim; Sarandöl, Emre; Aydınlar, Ali; Keçebaş, Mesut; GÜLLÜLÜ, NAZMİYE SÜMEYYE; Sağ, Saim; Açıkgöz, Ebru; Besli, Feyzullah; ŞENTÜRK, TUNAY; Kaderli, Aysel Aydın; ÖZDEMİR, BÜLENT; Baran, İbrahim; SARANDÖL, EMRE; AYDINLAR, ALİ; Tıp Fakültesi; Biyokimya Ana Bilim Dalı; 0000-0002-6206-8700; C-1517-2017; ABE-1716-2020; AAW-9185-2020; AAI-6632-2021; JKQ-3658-2023; JGR-6552-2023; CBS-6076-2022; DXE-4816-2022; CXL-7581-2022; JHE-3353-2023; CDA-1396-2022
  • No Thumbnail Available
    Publication
    Index of cardiac-electrophysiological balance in relapsing-remitting multiple sclerosis patients treated with fingolimod
    (Elsevier Sci Ltd, 2023-06-16) Günay-Polatkan, S.; GÜNAY POLATKAN, ŞEYDA; SIĞIRLI, DENİZ; Güllü, G.; GÜLLÜ, GİZEM; Sığırlı, Deniz; Koç, E. R.; KOÇ, EMİNE RABİA; Aydınlar, A.; AYDINLAR, ALİ; Turan, O. F.; TURAN, ÖMER FARUK; Tıp Fakültesi; Kardiyoloji Ana Bilim Dalı; 0000-0002-0264-7284; A-7083-2015
    Background: Fingolimod is indicated for the treatment of relapsing-remitting multiple sclerosis (RRMS) and also targets cardiovascular system due to receptors on cardiomyocytes. Results of previous studies are controversial for the effect of fingolimod in terms of ventricular arrhythmias. Index of cardio-electrophysiological balance (iCEB) is a risk marker for predicting malignant ventricular arrhythmia. There is no evidence on the effect of fingolimod on iCEB in patients with relapsing-remitting multiple sclerosis (RRMS). The aim of this study was to evaluate iCEB in patients with RRMS treated with fingolimod .Methods: A total of 86 patients with RRMS treated with fingolimod were included in the study. All patients underwent a standard 12-lead surface electrocardiogram at initiation of treatment and 6 h after treatment. Heart rate, RR interval, QRS duration, QT, QTc (heart rate corrected QT), T wave peak-to-end (Tp-e) interval, Tp-e/QT, Tp-e/QTc, iCEB (QT/QRS) and iCEBc (QTc/QRS) ratios were calculated from the electrocardiogram. QT correction for heart rate was performed using both the Bazett and Fridericia formulas. Pre-treatment and posttreatment values were compared.Results: Heart rate was significantly lower after fingolimod treatment (p< 0.001). While the post-treatment values of RR and QT intervals were significantly longer (p< 0.001) and post-treatment iCEB was higher (median [Q1Q3], 4.23 [3.95-4.50] vs 4.53 [4.18-5.14]; p< 0.001), it was found that there was no statistically significant change in iCEB and other study parameters derived using QT after correcting for heart rate using both of two formulas.Conclusions: In this study, it was found that fingolimod did not statistically significantly change any of the heart rate-corrected ventricular repolarization parameters, including iCEBc, and it is safe in terms of ventricular arrhythmia.
  • Thumbnail Image
    Publication
    Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey
    (Kare Yayınevi, 2017-07-01) Sağ, Saim; Kaderli, Aysel Aydın; Yıldız, Abdülmecit; Gül, Bülent Cuma; Özdemir, Bülent; Baran, İbrahim; Güllülü, Sümeyye; Aydınlar, Ali; Çavuşoğlu, Yüksel; Sağ, Saim; Kaderli, Aysel Aydın; YILDIZ, ABDULMECİT; GÜL, CUMA BÜLENT; ÖZDEMİR, BÜLENT; Baran, İbrahim; GÜLLÜLÜ, NAZMİYE SÜMEYYE; AYDINLAR, ALİ; Tıp Fakültesi; Kardiyoloji Ana Bilim Dalı; AAI-6632-2021; AAW-9185-2020; A-7063-2018; CXL-7581-2022; HIG-9032-2022; JHE-3353-2023; CDA-1396-2022; JGR-6552-2023
    Objective: The aim of the present study was to assess the efficacy and safety of tolvaptan for severe hyponatremia (SH) in hypervolemic heart failure (HF) patients within daily clinical practice.Methods: We restrospectively reviewed our database on tolvaptan as an add-on treatment in hypervolemic patients admitted to our clinic due to deterioration of HF and having hyponatremia resistant to standard therapy. Severe hyponatremia was defined as serum sodium concentration <= 125 mEq/L. The database included demographic, clinical, laboratory, and echocardiographic findings on admission, and numerous outcome measures for oral tolvaptan treatment were used to assess its efficacy and safety.Results: The study group consisted of 56 hypervolemic HF patients with severe hyponatremia (25 female and 31 male) with mean age of 66 years. All patients received a single dose of tolvaptan 15 mg daily for an average of 3.2 days due to severe hyponatremia. Sodium and potassium concentrations, fluid intake, and urine volume increased (p<0.0001, p=0.037, p<0.0001, and p<0.0001, respectively), whereas furosemide dosage, body weight, heart rate, systolic and diastolic blood pressure, and New York Heart Association class decreased significantly in response to tolvaptan treatment, without a rise in serum creatinine or urea concentrations (p<0.0001, p<0.0001, p=0.001, p<0.049, p<0.009 ve p=0.001, respectively).Conclusion: In this retrospective, single-centered study conducted in a small group of Turkish patients, short-term treatment with low-dose tolvaptan added to standard therapy of hypervolemic HF patients with severe hyponatremia was well tolerated with a low rate of major side effects and was effective in correcting severe hyponatremia.
  • No Thumbnail Available
    Publication
    Evaluation of serum levels of vaspin and visfatin and their relationship with coronary artery disease severity in stabil angina pectoris patients
    (Excerpta Medica Inc-elsevier Science Inc, 2014-04-01) Hamidi, Mehmet; Özdemir, Belgin; Dereli, Şeyda; Aydınlar, Ali; AYDINLAR, ALİ; Tıp Fakültesi; Kardiyoloji Ana Bilim Dalı
  • Thumbnail Image
    Publication
    Acute effect of hemodialysis on arterial elasticity
    (TÜBİTAK, 2015-01-01) Sağ, Saim; Yeşilbursa, Dilek; Yıldız, Abdülmecit; Dilek, Kamil; Şentürk, Tunay; Serdar, Osman Akın; Aydınlar, Ali; Sağ, Saim; YEŞİLBURSA, DİLEK; YILDIZ, ABDULMECİT; DİLEK, KAMİL; ŞENTÜRK, TUNAY; SERDAR, OSMAN AKIN; AYDINLAR, ALİ; Tıp Fakültesi; Kardiyoloji Ana Bilim Dalı; 0000-0003-1744-8883; 0000-0001-8404-8252; AAW-9185-2020; C-1517-2017; AAF-5116-2019; AAI-6632-2021; EHA-0046-2022; HIG-9032-2022; EUF-5229-2022
    Background/aim: Reduced arterial elasticity is an independent predictor of cardiovascular mortality in patients with end-stage renal disease (ESRD). Hemodialysis (HD) treatment per se can bring additional risk factors for vascular disease. Our study was designed to determine whether a single hemodialysis session leads to an acute alteration in parameters of arterial elasticity in ESRD.Materials and methods: In this study, 58 patients undergoing chronic hemodialysis and 29 healthy controls were enrolled. Large artery elasticity index (LAEI) and the small artery elasticity index (SAEI) were measured by applanation tonometry. The acute effect of a hemodialysis session on arterial elasticity indices was assessed by comparison of prehemodialysis and posthemodialysis determinations.Results: At baseline, LAEI did not differ significantly in patients compared with controls. In contrast, the SAEI was significantly lower in patients (4.1 +/- 2.6 mL/mmHg x 100) than in healthy individuals (8.9 +/- 3.4 mL/mmHg x 100, P < 0.05). In patients with ESRD, no significant changes in LAEI was observed after HD, but SAEI deteriorated significantly (from 4.1 +/- 2.6 mL/mmHg x 100 to 3.4 +/- 2.3, P < 0.05).Conclusion: We conclude that ESRD patients face a significant reduction in SAEI, which is exacerbated by a dialysis procedure.
  • No Thumbnail Available
    Publication
    Association of epicardial adipose tissue thickness by echocardiography and heart rate recovery in metabolic syndrome
    (Elsevier, 2013-10-29) Böyük, Ferit; Özdemir, Bülent; Sağ, Saim; Şentürk, Tunay; Kaderli, Aysel Aydın; Güllülü, Sümeyye; Aydınlar, Ali; Böyük, Ferit; ÖZDEMİR, BÜLENT; Sağ, Saim; ŞENTÜRK, TUNAY; Kaderli, Aysel Aydın; GÜLLÜLÜ, NAZMİYE SÜMEYYE; AYDINLAR, ALİ; Tıp Fakültesi; Kardiyoloji Bölümü; C-1517-2017; AAI-6632-2021; AAW-9185-2020; JIX-2728-2023; JHE-3353-2023; CXL-7581-2022; JGR-6552-2023